Skip to main content
. 2018 Sep 28;24(4):521–528. doi: 10.1634/theoncologist.2018-0290

Figure 4.

image

Time‐to‐event analysis of corticosteroid initiation in second‐line treatment with BEV versus placebo. A deterioration in health‐related quality of life (HRQoL) was defined as a decrease of ≥10 points from randomization on the respective functional scale/global health status or an increase of ≥10 points from randomization on the respective symptom/neurological deficit subscales; time to HRQoL deterioration was defined as the time from randomization to HRQoL deterioration or second‐line progression or death due to any cause. Abbreviations: BEV, bevacizumab; CCNU, lomustine; CI, confidence interval; HR, hazard ratio.